SAN DIEGO, June 12 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced the appointment of Craig Johnson to the Company's Board of Directors.
"We are pleased to welcome Mr. Johnson to Ardea as an independent member of our Board of Directors," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "Given his broad financial expertise within the life-sciences industry, he will chair our Audit Committee. We look forward to his insight and guidance as we continue to build our organization."
Craig Johnson is the vice president and chief financial officer of TorreyPines Therapeutics, Inc., where he has served in that capacity since joining the company in 2004. From 1994 to 2004, Mr. Johnson was employed by MitoKor, Inc. and last held the position of chief financial officer and senior vice president of operations. Prior to joining MitoKor, he was a senior financial executive for several early-stage technology companies. From 1984 to 1988, Mr. Johnson worked for the accounting firm Price Waterhouse LLP. He has been actively involved in the Association of Bioscience Financial Officers since 1998. Mr. Johnson received his B.B.A. in accounting from the University of Michigan and is a certified public accountant.
About Ardea Biosciences
Ardea Biosciences, Inc., of San Diego, California, is a biotechnology
company focused on the discovery and development of small-molecule
therapeutics for the treatment of HIV, cancer and inflammatory diseases,
including gout. We have four drug candidates in clinical trials and others
in preclinical development and discovery. Our most advanced development
candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor
(NNRTI), which is in a Phas
|SOURCE Ardea Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved